Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma
Abstract Gut microbiota has been associated with carcinogenesis and immune regulation. While there is evidence supporting its influence on immunotherapy response in melanoma, its impact on BRAF/MEK-targeted therapy remains unexplored. This study assessed gut microbiota composition and immune-associa...
Saved in:
| Main Authors: | Mora Guardamagna, Miguel-Angel Berciano-Guerrero, Rocío Lavado-Valenzuela, Édouard Auclin, Juan Luis Onieva-Zafra, Isaac Plaza-Andrades, Javier Oliver, Alicia Garrido-Aranda, Elisabeth Perez-Ruiz, Martina Álvarez, María Carmen Ocaña, María Isabel Queipo-Ortuño, Isabel Barragán, Antonio Rueda-Dominguez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-11054-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01) -
Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01) -
Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study
by: Ken Horisaki, et al.
Published: (2025-04-01) -
High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01) -
CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022-07-01)